创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction of iHuPDX model features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-11 15:46
  • Views:

(Summary description)With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features

InnoModels: Introduction of iHuPDX model features

(Summary description)With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-11 15:46
  • Views:
Information

With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features.
I. Homogenized modeling of the same batch of samples
InnoModels Bio's iHuPDX model ensures homogenization of samples between batches by modeling cell suspensions. This means that there is a high degree of consistency in the growth rate and biological characteristics of individual samples within the same batch. This homogenization modeling method not only lays a solid foundation for the stability of the model, but also provides a strong guarantee for the reliability and reproducibility of the experimental results.

 


Stability and Consistency of Same-Generation Transmission
The homogenization of the same batch of samples ensures the stability of the same generation and after the transmission. In the long-term research process, the iHuPDX model can maintain consistent growth and efficacy characteristics, which makes the experimental results more reliable. This stability and consistency of sibling transmission makes the model have a wide range of application prospects in the fields of drug development and disease treatment.
Early and uniform growth, optimal efficacy experimental window
The iHuPDX model of InnoModels Biotechnology provides an optimal experimental window for efficacy experiments by realizing uniform growth at an early stage. Conducting efficacy experiments in the P2-P5 generation can more accurately reflect the therapeutic effect of the drug on the disease, providing strong support for drug development. At the same time, the early uniform growth characteristics also make the model more advantageous in disease simulation and treatment strategy research.
In conclusion, the iHuPDX model of InnoModels provides a new perspective and tool for biomedical research with its unique features of homogenization modeling of samples from the same batch, stability and consistency of sibling transmission, and early uniform growth. The application of this model is expected to promote the development of personalized medicine and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司